Progressive hypertrophy regression with sustained pressure reduction in hypertension: The Losartan Intervention for Endpoint Reduction study
Diabetes Mellitus, Type 2
Hypertrophy, Left Ventricular
Sustained BP reduction in hypertensive patients with target organ damage causes continued decrease in echocardiographic LV mass and prevalence of anatomic LVH for at least 2 years despite only small BP decreases after the first year of blinded therapy. These data document cardiac benefit of sustained BP control and suggest that maximum LVH regression with effective antihypertensive treatment requires at least 2 years.